Form 4: Fulgent Genetics Director Michael Nohaile Reports Stock Transactions

Director Michael Nohaile reports acquisition and disposal of Fulgent Genetics stock and stock options.

Summary

• On May 15, 2025, Michael Nohaile, a director of Fulgent Genetics, reported transactions involving the company's stock.
• Nohaile acquired 4,491 shares of common stock and disposed of 19,020 shares.
• He also acquired options to purchase 6,311 shares of common stock at an exercise price of $20.04.
• The stock options vest over four years, with 1/4 vesting after 12 months and 1/16 vesting every three months thereafter, contingent upon continued service.
• The restricted stock units also vest over a period of four years, with 1/4th of such shares vesting 12 months after May 15, 2025, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon continued service with the Issuer.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency to investors regarding the actions of company leadership.

Stakeholder Impact

• Shareholders are informed about the stock transactions of a company director, providing transparency.

Key Dates

Keywords

Form 4, Fulgent Genetics, Stock Options, Stock Transactions, Beneficial Ownership, Director, FLGT, Michael Nohaile